Last reviewed · How we verify
Mometasone furoate - intranasal application
Mometasone furoate is a corticosteroid that reduces inflammation in the nasal passages by suppressing immune cell activity and inflammatory mediator release.
Mometasone furoate is a corticosteroid that reduces inflammation in the nasal passages by suppressing immune cell activity and inflammatory mediator release. Used for Allergic rhinitis, Nasal polyps, Chronic rhinosinusitis.
At a glance
| Generic name | Mometasone furoate - intranasal application |
|---|---|
| Also known as | Nasonex |
| Sponsor | Association Asthma, Bulgaria |
| Drug class | Intranasal corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Allergy / Immunology |
| Phase | FDA-approved |
Mechanism of action
As a glucocorticoid, mometasone furoate binds to glucocorticoid receptors in nasal tissue, leading to decreased production of inflammatory cytokines, chemokines, and adhesion molecules. This reduces recruitment and activation of inflammatory cells (eosinophils, mast cells, T cells) in the nasal mucosa, thereby alleviating symptoms of allergic and non-allergic rhinitis.
Approved indications
- Allergic rhinitis
- Non-allergic rhinitis
- Nasal polyps (adjunctive therapy)
Common side effects
- Headache
- Pharyngitis
- Epistaxis
- Nasal irritation
Key clinical trials
- Topical Steroids & Bacterial Decolonization for Radiation Dermatitis (PHASE2)
- 4"S" - Seasonal Symptoms Suppression Study (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: